New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma
Primary central nervous system lymphoma (PCNSL) is non-Hodgkin’s lymphoma (NHL) confined to the central nervous system. Most of the patients eventually develop relapsed/refractory (R/R) PCNSL, and the overall prognosis for PCNSL remains dismal. Recently, gene sequencing, transcriptome sequencing, an...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1438001/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024629379268608 |
|---|---|
| author | Chuanwei Yang Chuanwei Yang Xiaohui Ren Xiaohui Ren Yong Cui Yong Cui Haihui Jiang Ming Li Ming Li Kefu Yu Shaoping Shen Shaoping Shen Mingxiao Li Xiaokang Zhang Xiaokang Zhang Xuzhe Zhao Xuzhe Zhao Qinghui Zhu Qinghui Zhu Xingyao Bu Song Lin Song Lin Song Lin |
| author_facet | Chuanwei Yang Chuanwei Yang Xiaohui Ren Xiaohui Ren Yong Cui Yong Cui Haihui Jiang Ming Li Ming Li Kefu Yu Shaoping Shen Shaoping Shen Mingxiao Li Xiaokang Zhang Xiaokang Zhang Xuzhe Zhao Xuzhe Zhao Qinghui Zhu Qinghui Zhu Xingyao Bu Song Lin Song Lin Song Lin |
| author_sort | Chuanwei Yang |
| collection | DOAJ |
| description | Primary central nervous system lymphoma (PCNSL) is non-Hodgkin’s lymphoma (NHL) confined to the central nervous system. Most of the patients eventually develop relapsed/refractory (R/R) PCNSL, and the overall prognosis for PCNSL remains dismal. Recently, gene sequencing, transcriptome sequencing, and single-cell sequencing platforms have provided a large amount of data revealing the mechanisms underlying the pathogenesis and drug resistance in PCNSL, including the activation of the NF-κB signaling pathway in tumor cells, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Advances in molecular pathology studies for PCNSL have led to identifying new therapeutic targets and developing novel drugs. New therapeutic strategies, such as creating small molecule targeted agents, immunomodulatory drugs, immune checkpoint inhibitors, and chimeric antigen receptor T (CAR-T) cell therapy, have brought new hope for patients with PCNSL, especially for R/R PCNSL. This review presents recent advances in the treatment of PCNSL, reviews and discusses the efficacy and challenges of targeted therapy and immunotherapy, and provides an outlook on the future development of PCNSL treatment strategies. |
| format | Article |
| id | doaj-art-c030830519c84755a6df75d6465e41f4 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-c030830519c84755a6df75d6465e41f42025-08-20T03:01:03ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14380011438001New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphomaChuanwei Yang0Chuanwei Yang1Xiaohui Ren2Xiaohui Ren3Yong Cui4Yong Cui5Haihui Jiang6Ming Li7Ming Li8Kefu Yu9Shaoping Shen10Shaoping Shen11Mingxiao Li12Xiaokang Zhang13Xiaokang Zhang14Xuzhe Zhao15Xuzhe Zhao16Qinghui Zhu17Qinghui Zhu18Xingyao Bu19Song Lin20Song Lin21Song Lin22Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaNational Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor, Beijing, ChinaPrimary central nervous system lymphoma (PCNSL) is non-Hodgkin’s lymphoma (NHL) confined to the central nervous system. Most of the patients eventually develop relapsed/refractory (R/R) PCNSL, and the overall prognosis for PCNSL remains dismal. Recently, gene sequencing, transcriptome sequencing, and single-cell sequencing platforms have provided a large amount of data revealing the mechanisms underlying the pathogenesis and drug resistance in PCNSL, including the activation of the NF-κB signaling pathway in tumor cells, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Advances in molecular pathology studies for PCNSL have led to identifying new therapeutic targets and developing novel drugs. New therapeutic strategies, such as creating small molecule targeted agents, immunomodulatory drugs, immune checkpoint inhibitors, and chimeric antigen receptor T (CAR-T) cell therapy, have brought new hope for patients with PCNSL, especially for R/R PCNSL. This review presents recent advances in the treatment of PCNSL, reviews and discusses the efficacy and challenges of targeted therapy and immunotherapy, and provides an outlook on the future development of PCNSL treatment strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1438001/fullprimary central nervous system lymphomahigh-dose methotrexatetargeted therapyimmunotherapyclinical trial |
| spellingShingle | Chuanwei Yang Chuanwei Yang Xiaohui Ren Xiaohui Ren Yong Cui Yong Cui Haihui Jiang Ming Li Ming Li Kefu Yu Shaoping Shen Shaoping Shen Mingxiao Li Xiaokang Zhang Xiaokang Zhang Xuzhe Zhao Xuzhe Zhao Qinghui Zhu Qinghui Zhu Xingyao Bu Song Lin Song Lin Song Lin New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma Frontiers in Immunology primary central nervous system lymphoma high-dose methotrexate targeted therapy immunotherapy clinical trial |
| title | New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| title_full | New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| title_fullStr | New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| title_full_unstemmed | New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| title_short | New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| title_sort | new hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma |
| topic | primary central nervous system lymphoma high-dose methotrexate targeted therapy immunotherapy clinical trial |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1438001/full |
| work_keys_str_mv | AT chuanweiyang newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT chuanweiyang newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xiaohuiren newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xiaohuiren newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT yongcui newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT yongcui newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT haihuijiang newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT mingli newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT mingli newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT kefuyu newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT shaopingshen newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT shaopingshen newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT mingxiaoli newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xiaokangzhang newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xiaokangzhang newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xuzhezhao newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xuzhezhao newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT qinghuizhu newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT qinghuizhu newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT xingyaobu newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT songlin newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT songlin newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma AT songlin newhopesandchallengesintargetedtherapyandimmunotherapyforprimarycentralnervoussystemlymphoma |